Committee Unblinds Phase III Zytiga Study
USPSTF and ACS Recommend Less Frequent Cervical Cancer Screenings and Pap Smears
Tobacco Control and Prevention Saved 795,000 Lives Between 1975-2000, Study Shows
Five-year Childhood ALL Survival Increased To 90.4 Percent by 2005
Study: CYP2D6 Genotypes Are Unreliable Predictors of Benefit
Study: Freezing Secondary Tumors Helpful in Metastatic Breast Cancer
Women Who Received CMF Chemotherapy Score Lower On Cognitive Skill Exams
Three Studies Demonstrate Oncotype DX Test Effectiveness
ACG Highlights Link Between Obesity and Colorectal Cancer
Olaparib Study Demonstrates No Changes In Overall Survival
Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study
Trials Approved by NCI CTEP For the Month of March
Trending Stories
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - Trump 2016: A look back at the 45th president’s impact on oncology
- A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment - At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS
- GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation
- Long-term risks from prostate cancer treatment detailed in new report
